These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33219533)

  • 21. Adverse reactions following transfusion of blood components, with a focus on some rare reactions: Reports to the International Haemovigilance Network Database (ISTARE) in 2012-2016.
    Politis C; Wiersum-Osselton J; Richardson C; Grouzi E; Sandid I; Marano G; Goto N; Condeço J; Boudjedir K; Asariotou M; Politi L; Land K
    Transfus Clin Biol; 2022 Aug; 29(3):243-249. PubMed ID: 35476961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products.
    Pohler P; Müller M; Winkler C; Schaudien D; Sewald K; Müller TH; Seltsam A
    Transfusion; 2015 Feb; 55(2):337-47. PubMed ID: 25134439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transfusion-associated graft-versus-host disease: report of an occurrence following the administration of irradiated blood.
    Lowenthal RM; Challis DR; Griffiths AE; Chappell RA; Goulder PJ
    Transfusion; 1993 Jun; 33(6):524-9. PubMed ID: 8516797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998.
    Andreu G; Morel P; Forestier F; Debeir J; Rebibo D; Janvier G; Hervé P
    Transfusion; 2002 Oct; 42(10):1356-64. PubMed ID: 12423521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports.
    Williamson LM; Lowe S; Love EM; Cohen H; Soldan K; McClelland DB; Skacel P; Barbara JA
    BMJ; 1999 Jul; 319(7201):16-9. PubMed ID: 10390452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review of transfusion-associated graft-versus-host disease.
    Kopolovic I; Ostro J; Tsubota H; Lin Y; Cserti-Gazdewich CM; Messner HA; Keir AK; DenHollander N; Dzik WS; Callum J
    Blood; 2015 Jul; 126(3):406-14. PubMed ID: 25931584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: implications for universal irradiation of cellular blood components.
    Anderson K
    Transfusion; 2003 Dec; 43(12):1652-4. PubMed ID: 14641857
    [No Abstract]   [Full Text] [Related]  

  • 28. Gamma-irradiation of blood products following autologous stem cell transplantation: surveillance of the policy of 35 centers.
    Weiss B; Hoffmann M; Anders C; Hellstern P; Schmitz N; Uppenkamp M;
    Ann Hematol; 2004 Jan; 83(1):44-9. PubMed ID: 14551741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Institution and significance of the new guidelines for prevention of transfusion associated graft versus host disease].
    Asai T
    Nihon Rinsho; 1997 Sep; 55(9):2296-304. PubMed ID: 9301293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of irradiated blood components: practice parameter.
    Przepiorka D; LeParc GF; Stovall MA; Werch J; Lichtiger B
    Am J Clin Pathol; 1996 Jul; 106(1):6-11. PubMed ID: 8701934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transfusion of pathogen-reduced platelet components without leukoreduction.
    Sim J; Tsoi WC; Lee CK; Leung R; Lam CCK; Koontz C; Liu AY; Huang N; Benjamin RJ; Vermeij HJ; Stassinopoulos A; Corash L; Lie AKW
    Transfusion; 2019 Jun; 59(6):1953-1961. PubMed ID: 30919465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing transfusion reaction risks for various plasma products - an analysis of 7 years of ISTARE haemovigilance data.
    Saadah NH; van der Bom JG; Wiersum-Osselton JC; Richardson C; Middelburg RA; Politis C; Renaudier P; Robillard P; Schipperus MR
    Br J Haematol; 2018 Mar; 180(5):727-734. PubMed ID: 29318576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Supportive transfusion therapy in cancer patients with acquired defects of hemostasis.
    Federici AB; Intini D; Lattuada A; Vanelli C; Arrigoni L; Sacchi E; Russo U
    Thromb Res; 2014 May; 133 Suppl 2():S56-62. PubMed ID: 24862147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transfusion errors - can they be eliminated?
    Bolton-Maggs PHB; Watt A
    Br J Haematol; 2020 Apr; 189(1):9-20. PubMed ID: 31792932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proposing a Model for the National Hemovigilance Information System in Iran.
    Asadi F; Ramezanghorbani N
    J Med Life; 2020; 13(2):211-218. PubMed ID: 32742516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Transfusion-associated graft-vs-host disease].
    Lillevang ST; Kristensen T
    Ugeskr Laeger; 1992 Oct; 154(43):2964-8. PubMed ID: 1462384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse outcomes of blood transfusion in children: analysis of UK reports to the serious hazards of transfusion scheme 1996-2005.
    Stainsby D; Jones H; Wells AW; Gibson B; Cohen H;
    Br J Haematol; 2008 Apr; 141(1):73-9. PubMed ID: 18324969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Indications for irradiated blood components: dose and side effects].
    Eiermann TH
    Beitr Infusionsther; 1993; 31():70-3. PubMed ID: 7693267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transfusion and hemovigilance in pediatrics.
    Bolton-Maggs PH
    Pediatr Clin North Am; 2013 Dec; 60(6):1527-40. PubMed ID: 24237986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transfusion-associated circulatory overload in Ireland: a review of cases reported to the National Haemovigilance Office 2000 to 2010.
    Piccin A; Cronin M; Brady R; Sweeney J; Marcheselli L; Lawlor E
    Transfusion; 2015 Jun; 55(6):1223-30. PubMed ID: 25522667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.